Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline
Vas Narasimhan has been CEO at Novartis for just a little more than a year since his promotion from development chief. And in today’s investor meeting, after spinning off Alcon and putting the wheels in motion to do a makeover at the suffering generics wing Sandoz, the spotlight is being turned straight at his prized possession: the pipeline.
He has a lot to boast about. But let’s start with the “25-plus” potential blockbusters in the clinic, along with 10-plus launches by 2021.
Many of these drugs are no stranger to the center ring, but there are some new additions to the lineup.
Basic subscription required
Unlock this story instantly and join 57,900+ biopharma pros reading Endpoints daily — and it's free.